Hodgkin’s disease in adults: the royal medical services experience

Mohammad Obeidat, Ayman Abu Kamar, Abdmajid Arabeat, Majdy Al-jdayeh, Ahmad Bawaeneh

Abstract


Background: The aim of this study to examine our experience in the presentation and management and to determine the factors that potentially influenced the outcome in 96 patients with Hodgkin’s lymphoma.

Methods: A retrospective study done at oncology unit in royal medical services hospitals, a total 96 patient whom diagnosed with Hodgkin’s lymphoma between 2005 and 2013, data include age, sex of patients, presenting and duration of symptoms, staging of disease, and prognosis of disease.

Results: 66 males and 30 females, the most common enlarged lymph node was at cervical region. The most common histopathology subtype was nodular sclerosis. Most of our patients were staged as stage 4. Systemic symptoms developed in 50 (52%) patients. The most common site of extralymphatic involvement was lung. Complete remission was noted in all 29 patients whom presented with early stages of disease and less in advanced stages. Failure of remission post treatment was noticed more in mixed cellularity and lymphocyte rich subtypes. On regular follow up of patients 8 patients whom were in complete remission developed relapse of disease; mean time of relapse was 9 months post remission.

Conclusion: Hodgkin’s lymphoma has high rates of cure. Epidemiological, clinical, histological and therapeutic results in our series are similar to those Western series. Long term evaluation is necessary to assess relapse and late toxicity treatment.


Keywords


Hodgkin’s lymphoma, Prognosis, Epidemiology

Full Text:

PDF

References


Ansell SM. Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86:851-8.

Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62(1):10-29.

Connors JM. Hodgkin’s lymphoma: the great teacher. N Engl J Med. 2011;365:264-5.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO Book. 4th ed. Lyon: IARC Library; 2008: 326-334.

Glaser SL, Jarrett RF. The epidemiology of Hodgkin’s disease. Baillieres Clin Haematol. 1996;9:401-16.

Poppema S. The diversity of the immunohistological staining pattern of Sternberg-Reed cells. J Histochem Cytochem. 1980;28:788-91.

Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of microenvironment. J Clin Oncol. 2011;29:1812-26.

Küppers R, Schmitz R, Distler V, Renné C, Bräuninger A, Hans mann ML. Pathogenesis of Hodgkin’s lymphoma. Eur J Haematol. 2005;75(Suppl 66):26-33.

Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812-26.

Josting A. Prognostic factors in Hodgkin’s lymphoma. Exp Rev Hematol. 2010;3:583-92.

Küppers R. Molecular biology of Hodgkin’s lymphoma. Adv Cancer Res. 2002;84:277-312.

Eichenauer DA, Engert A, Dreyling M. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):55-8.

MacFarlane GL, Evstifeeva T, Boyle P, Glufferman S. International patterns in the occurrence of Hodgkin’s disease in children and young adult males. Int J Cancer. 1995;61:165-9.

MacMahon B, Cole P, Newell GR. Hodgkin’s disease: one entity or two? Lancet. 1971;1:240-1.

Percy CL, Smith MA. Lymphomas and reticuloendothelial neoplasms. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al., eds. Cancer Incidence and Survival Among Children and Adolescents: United States - SEER Program 1975–1995. National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999: 1-182.

Yung L, Linch D. Hodgkin’s Lymphoma. Lancet. 2003 Mar;361:943-51.

Stein RS. Hodgkin disease. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe’s Clinical Hematology. 10th ed. Baltimore (MD): Williams and Wilkins; 1998: 2538-2571.

Pastore G, Magnani C, Verdecchia A, Pession A, Viscomi S, Coebergh JW. Survival of childhood lymphomas in Europe, 1978-1992: a report from the EUROCARE study. Eur J Cancer. 2001;37:703-10.

Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. Lymphoma in adolescents and young adults. Semin Oncol. 2009;36:381-418.

Connors JM. Hodgkin’s lymphoma: the great teacher. N Engl J Med. 2011;365:264-5.

McElwain TJ. Hodgkin’s and Non-Hodgkin’s lymphoma. Br J Hosp Med. 1984;1:10-20.

Grimm S, Chamberlain M. Hodgkin’s lymphoma: a review of neurologic complications. Adv Hematol. 2011;2011:1-7.

Mirijello A, Addolorato G, Landolfi R. Hodgkin’s lymphoma presenting as chest pain. Int J Clin Med. 2013;4:32-4.

Drouet F, Cahu X, Pointreau Y, Denis F, Mahé MA. Lymphome de Hodgkin. Cancer Radiother. 2010;14:S198-209.

Glaser S, Dorfman R, Clarke C. Expert review of the diagnosis and histologic classification of Hodgkin’s disease in a population-based cancer registry. Cancer. 2001;92:218-24.

Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC. Clonality in nodular lymphocyte-predominant Hodgkin’s disease. N Engl J Med. 1997;337:459-65.

Fanale MA, Lai CM, McLaughlin, Romaguera JE, Fayad L, Hagemeister F, Samaniego F, et al. Outcome of nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) patients treated with R-CHOP. Am Soc Hematol (Blood). 2010;116:2812.

Kuppers R, Engert A, Hansmann M. Hodgkin lymphoma. J Clin. Invest. 2012;122(10):3439-47.

DeVita VT Jr, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA. Hodgkin’s lymphoma. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA, eds. Devita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. New York, NY: Lippincott Williams & Wilkins; 2011: 914-917.

Aridgides P, Bogart J, Shapiro A, Gajra A. PET response-guided treatment of Hodgkin’s lymphoma: a review of the evidence and active clinical trials. Adv Hematol. 2011;2011:309237.

Yeoh KW, Mikhaeel NG. Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy? Int J Radiat Oncol Biol Phys. 2013;85:14-20.

Kuppers R, Engert A, Hansmann M. Hodgkin’s lymphoma. J Clin Invest. 2012;122(10):3439-47.

Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer. 1997;33:848-53.

Healey EA, Tarbell NJ, Kalish LA, Silver B, Rosenthal DS, Marcus K, et al. Prognostic factors for patients with Hodgkin’s disease in first relapse. Cancer. 1993;71:2613-20.

Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer. 1996;78:1293-9.